Report of Foreign Issuer (6-k)
May 22 2017 - 11:54AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
22 May
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
GlaxoSmithKline plc (the '
Company
')
Transaction notification
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
a)
|
Name
|
Mr P C Thomson
|
b)
|
Position/status
|
President, Global Affairs
|
c)
|
Initial notification/
amendment
|
Initial notification
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
GlaxoSmithKline plc
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
a)
|
Description
of
the
financial
instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
b)
|
Nature
of
the
transaction
|
Acquisition of
Ordinary Shares on 19 May 2017 following the exercise of options
granted on 30 October 2013 at the option price of £12.47 per
Ordinary Share under the Company's ShareSave
Plan.
|
c)
|
Price(s)
and
volume(s)
|
Price(s)
|
Volume
(s)
|
£12.47
|
288
|
d)
|
Aggregated information
Aggregated volume Price
|
n/a (single transaction)
|
e)
|
Date of
the
transaction
|
2017-05-19
|
f)
|
Place
of
the transaction
|
London Stock Exchange (XLON)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: May
22, 2017
|
|
|
|
|
By: VICTORIA
WHYTE--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2024 to May 2024
GSK (NYSE:GSK)
Historical Stock Chart
From May 2023 to May 2024